Ligand · MRY
MRY · Meso-erythritol
MRY, Meso-erythritol (C4 H10 O4, 122.1 g/mol), in the MolNFT structures on GenesisL1: bound in 10 records (8 PDB entries). Every binding site with its residues within 4.5 Å, the residues it binds most and the ligands found with it.
- Component
- MRY
- Formula
- C4 H10 O4
- Class
- ligand
- Structures
- 10
- PDB entries
- 8
Binding sites
MRY in 10 structures; the first of them:
- 5EUK · Cetuximab Fab in complex with F3H meditope variant · MRY C301 · binds GLN155, SER156, GLY157, ASN158, SER159
- 5U3D · Structure of meditope enabled trastuzumab I83E variant · MRY A301 · binds GLN37, ARG39, ARG45, ARG61, PHE62, GLU81, ASP82
- 5U5M · Crystal structure of I83E meditope-enabled trastuzumab with azido-meditope · MRY B301 · binds GLU155, PRO156, VAL157, ALA175, LEU185, 2GX5, SER6
- 5T1K · Cetuximab Fab in complex with CQFDA(PH)2STRRLKC · MRY C301 · binds GLN155, SER156, GLY157
- 5U3D · Structure of meditope enabled trastuzumab I83E variant · MRY A301 · binds GLN37, ARG39, ARG45, ARG61, PHE62, GLU81, ASP82
- 5U5F · Meditope enabled trastuzumab I83E variant in complex with (ac) CQFDA(PH)2STRRLRCGGSK · MRY B301 · binds TYR152, GLU155, PRO156, VAL157, ALA175, LEU185, 2GX5, SER6
- 5U5M · Crystal structure of I83E meditope-enabled trastuzumab with azido- meditope · MRY B301 · binds GLU155, PRO156, VAL157, ALA175, LEU185, 2GX5, SER6
- 5U6A · Crystal structure of I83E meditope-enabled trastuzumab with azido- PEG3-meditope · MRY B301 · binds GLU155, PRO156, VAL157, ALA175, LEU185, 2GX5, SER6
- 6UGV · Crystal structure of the Fab fragment of anti-tnfa antibody infliximab (remicade) in a… · MRY H301 · binds GLY141, THR142, THR190, PRO192
- 7C64 · Crystal structure of beta-glycosides-binding protein of ABC transporter in an open state… · MRY A511 · binds ARG354, THR355, GLN358
Residues it binds most
ARG 4, SER 6, GLN 6, GLU 6, PRO 6, THR 4, 2GX 4, ALA 4, LEU 4, VAL 4 (residue and the binding sites it lines).
Found with
GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.